Dossiers d'AMM à étudier par le Comité Technique des Spécialités Pharmaceutiques du 06/02/2024.
Pour ce comité technique, l’ordre de passage des dossiers sera comme suit .
Spécialités Pharmaceutiques fabriquées localement :
* Produits déjà évalués lors des derniers Comités Techniques
N° | Médicament | DCI | Dosage | Forme Pharmaceutique | Présentation | TITULAIRE | VEIC | Type de demande | date du courrier |
1 | TEMOZOLOMIDE NEAPOLIS | TÉMOZOLOMIDE | 100 mg | Poudre pour solution pour perf | B/1FL | NEAPOLIS PHARMA | E | N | CS 29/01/2024 |
2 | APRIVA | APREMILAST | 10mg/20mg/30mg | Comprimé pelliculé | B/28 (4/10 mg+4/20 mg+20/30 mg | IBN AL BAYTAR | I | N | CS 31/01/2024 |
3 | APRIVA | APREMILAST | 30 mg | Comprimé pelliculé | B/60 | IBN AL BAYTAR | I | N | CS 31/01/2024 |
* Produits à évaluer pour la première fois au Comité Technique
N° | Médicament | DCI | Dosage | Forme Pharmaceutique | Présentation | TITULAIRE | VEIC | Type de demande | date du courrier |
1 | SACUVAL 100 | sacubitril+valsartan | 48.6mg/51.4mg | Comprimé pelliculé | B/30 | PHILADELPHIA PHARMA | E | N | 29/11/2023 |
2 | SACUVAL 200 | sacubitril+valsartan | 97.2mg/102.8mg | Comprimé pelliculé | B/30 | PHILADELPHIA PHARMA | E | N | 29/11/2023 |
3 | NOVAMOX | AMOXICILLINE | 1 gr | Comprime dispersible | B/21 | ADWYA | E | N | 14/12/2023 |
4 | NOVACLAV | AMOXICILLINE+ACIDE CLAVULANIQUE | 500 mg/62.5mg | Comprimé pelliculé | B/42 | ADWYA | E | N | 14/12/2023 |
5 | CYSTODOSE | FOSFOMYCINE | 3 g | Granulés pour solution buvable | B/4 sachets | SAIPH | E | N | 14/12/2023 |
6 | LIDOCA PLUS | LIDOCAINE+PRILOCAINE | 5% | Creme dermique | T/5 g | SIMED | E | N | 03/01/2024 |
7 | AMOXIL | AMOXICILLINE | 0.5 gr | Pdre p.prep.injectable | B/25 FL | UNIMED | E | N | 11/01/2024 |
8 | AMOXIL IM IV | AMOXICILLINE | 0.5 gr | Pdre p.prep.injectable | B/1flacon +solvant/5ml | UNIMED | E | V | 11/01/2024 |
9 | AMOXIL | AMOXICILLINE | 0.5 GR | Pdre p.prep.injectable | B/1FL/+S/5ml | UNIMED | E | V | 11/01/2024 |
10 | AMOXIL | AMOXICILLINE | 1 GR | Pdre p.prep.injectable | B/1FL/+S/5ml | UNIMED | E | V | 11/01/2024 |
11 | CEFTAZIM IV | CEFTAZIDIME | 2 gr | Pdre p.prep.injectable | B/1FL/ 20 ML+ set de transfert | UNIMED | E | V | 11/01/2024 |
12 | CEFTAZIM IM IV | CEFTAZIDIME | 1 gr | Pdre p.prep.injectable | B/1 fl s/solvant | UNIMED | E | V | 11/01/2024 |
13 | CEFTAZIM IM IV | CEFTAZIDIME | 0,5 gr | Pdre p.prep.injectable | B/1 fl s/solvant | UNIMED | E | V | 11/01/2024 |
14 | CIFLOXET 200 | CIPROFLOXACINE | 200 mg/100ml | Solution injectable | FL/100 ml | DORCAS | E | V | 11/01/2024 |
15 | CIFLOXET 200 | CIPROFLOXACINE | 200 mg/100ml | Solution injectable | B/6 flacons/100 ml | DORCAS | E | V | 11/01/2024 |
16 | CIPROJECT | CIPROFLOXACINE | 400 mg/200ml | Solution injectable pour perfu | poche/200 ml | UNIMED | E | V | 11/01/2024 |
17 | CIPROJECT | CIPROFLOXACINE | 200 mg//100ml | Solution injectable pour perfu | poche/100 ml | UNIMED | E | V | 11/01/2024 |
18 | CIPROJECT | CIPROFLOXACINE | 200 mg//100ml | Solution injectable pour perfu | poche multicouche/100 ml | UNIMED | E | V | 11/01/2024 |
19 | SIFLOKS | CIPROFLOXACINE | 500 MG | Comprimé pelliculé sécable | B/28 | TERIAK | E | V | 11/01/2024 |
20 | SIFLOKS | CIPROFLOXACINE | 500 MG | Comprimé pelliculé sécable | B/14 | TERIAK | E | V | 11/01/2024 |
21 | SIFLOKS | CIPROFLOXACINE | 750 MG | Comprimé pelliculé sécable | B/14 | TERIAK | E | V | 11/01/2024 |
22 | SIFLOKS | CIPROFLOXACINE | 750 MG | Comprimé pelliculé sécable | B/28 | TERIAK | E | V | 11/01/2024 |
23 | CIPROSAIPH | CIPROFLOXACINE | 500 mg | Comprimé pelliculé sécable | B/14 | SAIPH | E | V | 11/01/2024 |
24 | TAVACET 500 | LEVOFLOXACINE | 5 MG/ML | Solution injectable pour perfu | FL/100 ML | DORCAS | E | V | 11/01/2024 |
25 | TAVACET 500 | LEVOFLOXACINE | 5 mg/ml | Solution injectable pour perfu | B/ 6 flacons/ 100 ml | DORCAS | E | V | 11/01/2024 |
26 | TAVANIC | LEVOFLOXACINE | 500 MG | Comprimé pelliculé | B/5 | SANOFI AVENTIS PHARMA TUNISIE | E | V | 11/01/2024 |
27 | TAVANIC | LEVOFLOXACINE | 500 MG | Comprimé pelliculé | B/10 | SANOFI AVENTIS PHARMA TUNISIE | E | V | 11/01/2024 |
28 | TAVAFLOX | LEVOFLOXACINE | 500 mg | Comprimé pelliculé sécable | B/5 | TERIAK | E | V | 11/01/2024 |
29 | TAVAFLOX | LEVOFLOXACINE | 500 mg | Comprimé pelliculé sécable | B/10 | TERIAK | E | V | 11/01/2024 |
30 | LEVOX | LEVOFLOXACINE | 500 mg | Comprimé pelliculé sécable | B/10 | ADWYA | E | V | 11/01/2024 |
31 | LEVOX | LEVOFLOXACINE | 500 mg | Comprimé pelliculé sécable | B/5 | ADWYA | E | V | 11/01/2024 |
32 | LOVIK | LEVOFLOXACINE | 500 mg | Comprimé pelliculé sécable | B/10 | PHILADELPHIA PHARMA | E | V | 11/01/2024 |
33 | LOVIK | LEVOFLOXACINE | 500 mg | Comprimé pelliculé sécable | B/5 | PHILADELPHIA PHARMA | E | V | 11/01/2024 |
34 | CLAVUMOX | AMOXICILLINE+ACIDE CLAVULANIQUE | 500 mg/62.5 mg | Comprimé pelliculé | B/48 | GALPHARMA | E | N | 19/01/2024 |
35 | AZITHROCINE 250 | AZITHROMYCINE | 250 mg | Gélule | B/6 | SIPHAT | E | V | 30/01/2024 |
36 | ZITHROCARE | AZITHROMYCINE | 500 mg | Comprimé pelliculé | B/3 | PHARMACARE | E | V | 30/01/2024 |
37 | TARDIPEN | BENZATHINE BENZYLPENICILLINE | 1.200 MUI | Pdre p.prep.injectable | B/1 FL + Solvant /4 ml | UNIMED | E | V | 30/01/2024 |
38 | TARDIPEN | BENZATHINE BENZYLPENICILLINE | 0.6 MUI | Pdre p.prep.injectable | B/1 FL + Solvant / 2ml | UNIMED | E | V | 30/01/2024 |
39 | TARDIPEN | BENZATHINE BENZYLPENICILLINE | 1.200 MUI | Pdre p.prep.injectable | B/25 flacons | UNIMED | E | V | 30/01/2024 |
40 | BACTRIM NOURRISSONS ET ENFANTS | COTRIMOXAZOLE | 240 mg/5ml | Suspension buvable | FL/100 ML | TERIAK | E | V | 30/01/2024 |
41 | OFLOJECT | OFLOXACINE | 200 mg/40ml | Solution injectable pour perfu | B/10 poches PVC/40ML | UNIMED | E | V | 30/01/2024 |
42 | OFLOJECT | OFLOXACINE | 200 mg/40ml | Solution injectable pour perfu | B/10 Poches multicouches/40ML | UNIMED | E | V | 30/01/2024 |
43 | OFLOJECT | OFLOXACINE | 200 mg/40ml | Solution injectable | B/1FL/40 ml | UNIMED | E | V | 30/01/2024 |
44 | ADYFLU | OSELTAMIVIR | 75 mg | Gélule | B/10 | ADWYA | E | V | 30/01/2024 |
45 | PENI-V | PHENOXYMETHYLPENICILLINE | 1000 000 UI | Comprimé pelliculé sécable | B/12 | SAIPH | E | V | 30/01/2024 |
46 | BACTRIM FORTE | SULFAMETOPYRAZINE+TRIMETHOPRIME | 800 mg/160 mg | Comprimé | B/10 | TERIAK | E | V | 30/01/2024 |
47 | BACTRIM | SULFAMETOPYRAZINE+TRIMETHOPRIME | 400 mg/80 mg | Comprimé | B/20 | TERIAK | E | V | 30/01/2024 |
Spécialités Pharmaceutiques importées
* Produits déjà évalués lors des derniers Comités Techniques
N° | Médicament | DCI | Dosage | Forme Pharmaceutique | Présentation | TITULAIRE | VEIC | Type de demande | date du courrier |
1 | NASONEX | MOMETASONE | 50 MCG/DOSE | Susp NASAL | FL/140 DOSES | ORGANON TECHNIKA FRANCE | E | T | 01/04/2024 |
2 | Pemzek | Candesartan | 8 mg | comprimé | B/28 | ASTRA ZENECA SUISSE | E | T | 01/11/2024 |
3 | Pemzek | Candesartan | 16 mg | comprimé | B/28 | ASTRA ZENECA SUISSE | E | T | 01/11/2024 |
4 | KESIMPTA | OFATUMUMAB | 20 mg/0.4ml | SOL INJ | B/1STYLO | NOVARTIS PHARMA SCHWEIZ AG | N | 17/01/2024 | |
5 | TREMFYA | GUSELKUMAB | 100mg | SOL INJ | B/1 seringue pré-remplie | Janssen-Cilag International N.V | E | N | 31/01/2024 |
* Produits à évaluer pour la première fois au Comité Technique
Médicament | DCI | Dosage | Forme Pharmaceutique | Présentation | TITULAIRE | VEIC | Type de la demande | DATE RE | |
1 | SEMGLEE | INSULINE GLARGINE | 100 UI/ml | SOL INJ | B/5 stylos pré-remplis | Biosimilar Collaborations Ireland Limited ("BCIl") | V | T | 17/10/2023 |
2 | MYCOSTER VERNIS | CICLOPIROXOLAMINE | 8% | SOL EXTERNE | FL/3ML | PIERRE FABRE MEDICAMENT . | E | T | 26/10/2023 |
3 | MYCOSTER | CICLOPIROXOLAMINE | 1% | PDRE A USAGE EXTERNE | FL/30 GR | PIERRE FABRE MEDICAMENT . | E | T | 26/10/2023 |
4 | ABSTRAL | FENTANYL | 100 µg | COMP SUBL | B/10 | KYOWA KIRIN INC | V | N | 11/03/2023 |
5 | ABSTRAL | FENTANYL | 200 µg | COMP SUBL | B/10 | KYOWA KIRIN INC | V | N | 11/03/2023 |
6 | DIPROSTENE | BETAMETHASONE | 7 MG | SUSP INJ | B/1SER | Organon France | E | T | 11/07/2023 |
7 | REMSIMA SC | INFLIXIMAB | 120 mg | SOL INJ | B/2seringues prérempli | HIKMA Pharmaceuticals | E | N | 11/08/2023 |
8 | REMSIMA SC | INFLIXIMAB | 120 mg | SOL INJ | B/2 Stylos prérempli | HIKMA Pharmaceuticals | E | N | 11/08/2023 |
9 | REMSIMA SC | INFLIXIMAB | 120 mg | SOL INJ | B/1seringues préremplies | HIKMA Pharmaceuticals | E | N | 11/08/2023 |
10 | REMSIMA SC | INFLIXIMAB | 120 mg | SOL INJ | B/4 Stylos préremplis | HIKMA Pharmaceuticals | E | N | 11/08/2023 |
11 | REMSIMA SC | INFLIXIMAB | 120 mg | SOL INJ | B/4 seringues préremplies | HIKMA Pharmaceuticals | E | N | 11/08/2023 |
12 | REMSIMA SC | INFLIXIMAB | 120 mg | SOL INJ | B/1 stylo prérempli | HIKMA Pharmaceuticals | E | N | 11/08/2023 |
13 | ZINNAT | CEFUROXIME | 500 mg | Cp Pell | B/10 | SANDOZ PHARMACEUTICALS DD SLOVENIE | |||
14 | OLMESATAN MEDOXOMIL & AMLODIPINE /GENEPHARM | AMLODIPINE+OLMESARTAN MEDOXOMIL | 40 mg/5mg | COMP PEL | B/30 | GENEPHARM S.A | E | N | 12/12/2023 |
15 | OLMESATAN MEDOXOMIL & AMLODIPINE /GENEPHARM | AMLODIPINE+ OLMESARTAN MEDOXOMIL | 20 mg/5mg | COMP PEL | B/30 | GENEPHARM S.A | E | N | 12/12/2023 |
16 | OLMESATAN MEDOXOMIL & AMLODIPINE /GENEPHARM | AMLODIPINE+ OLMESARTAN MEDOXOMIL | 40 mg/10mg | COMP PEL | B/30 | GENEPHARM S.A | E | N | 12/12/2023 |
17 | CARDENSIEL | BISOPROLOL | 1.25 mg | COMP PEL | B/30 | Merck Santé s.a.s | E | N | 12/12/2023 |
18 | DIBASE | CHOLÉCALCIFÉROL | 50 000 UI /2.5ML | SOL BUV | B/ 1FL | ABIOGEN PHARMA S.p.A | E | N | 13/12/2023 |
19 | DIBASE | CHOLÉCALCIFÉROL | 100 000 UI /ML | SOL INJ | B/6 ampoules de 1ml | ABIOGEN PHARMA S.p.A | E | N | 13/12/2023 |
20 | DIBASE | CHOLÉCALCIFÉROL | 25 000 UI /2.5ML | SOL BUV | B/ 1FL monodose de 2.5 ml | ABIOGEN PHARMA S.p.A | E | N | 13/12/2023 |
21 | DIVINUSMET XR | DAPAGLIFLOZINE PROPANEDIOL / METFORMINE CHLORHYDRATE | 10 mg/1000 mg | COMP PEL | B/30 | HIKMA Pharmaceuticals | N | 13/12/2023 | |
22 | DIVINUSMET XR | DAPAGLIFLOZINE PROPANEDIOL / METFORMINE CHLORHYDRATE | 5 mg/1000 mg | COMP PEL | B/60 | HIKMA Pharmaceuticals | N | 13/12/2023 | |
23 | TOUJEO SOLOSTAR | INSULINE GLARGINE | 300 UI/ML | SOL INJ | B/3 STYLOS | SANOFI AVENTIS DEUTSCHLAND GmbH | V | V | CS 13/12/2023 |
24 | JANUMET | SITAGLIPTINE+METFORMINE | 50 mg/850mg | COMP PEL | B/56 | MERCK SHARP & DOHME BV | E | T | 13/12/2023 |
25 | SULIQUA | INSULINE GLARGINE + LIXISENATIDE | 100 Unités/ml + 50 µg/ml | SOL INJ | B/3 Stylos | SANOFI-AVENTIS FRANCE | V | N | 13/12/2023 |
26 | SULIQUA | INSULINE GLARGINE + LIXISENATIDE | 100 Unités /ml + 33 µg/ml | SOL INJ | B/3 Stylos | SANOFI-AVENTIS FRANCE | V | N | 13/12/2023 |
27 | BAXDELA | DELAFLOXACINE MEGLUMINE | 450 mg | COMP | B/20 | HIKMA Pharmaceuticals | N | CS 14/12/2023 | |
28 | BAXDELA | DELAFLOXACINE MEGLUMINE | 300 mg | PDRE PR PREP INJ | B/10FL/20ML | HIKMA Pharmaceuticals | N | CS 14/12/2023 | |
29 | MONURIL ADULTE | FOSFOMYCINE | 3 G | GRANULE PR SUSP BUV | B/1SACHET | ZAMBON FRANCE | E | V | CS 14/12/2023 |
30 | HEXAXIM | VACCIN D+T+C+P+HB+HIB | SUSP INJ | B/1 SER | SANOFI PASTEUR SA | E | V | CS 11/01/2024 | |
31 | CURACNE | ISOTRETINOINE | 40 MG | CAPSULE MOLLE | B/30 | PIERRE FABRE MEDICAMENT . | I | T | 24/01/2024 |
32 | LOXEN LP | CHLORHYDRATE DE NICARDIPINE | 50 MG | GELULE LP | B/60 | LABORATOIRE X,O | E | T | 29/01/2024 |
33 | TRANXENE | CLORAZEPATE DIPOTASSIQUE | 10 MG | GELULE | B/30 | NEURAXPHARM FRANCE | I | T | 29/01/2024 |
34 | AVASTIN | BEVACIZUMAB | 100 MG | SOL INJ PR PF | B/1FL | ROCHE PHARMA AG | E | V | CS 29/01/2024 |
35 | AVASTIN | BEVACIZUMAB | 400 MG | SOL INJ PR PF | B/1FL | ROCHE PHARMA AG | E | V | CS 29/01/2024 |
36 | CASODEX | BICALUTAMIDE | 50 MG | COMP ENROBE | B/30 | JUVISE PHARMACEUTICALS | V | T | CS 29/01/2024 |
37 | Keytuda | ||||||||
38 | EMEND | APREPITANT | 80mg/125mg | GELULE | B/3 | MERCK SHARP & DOHME BV | C | T | CS 29/01/2024 |
39 | ZAVICEFTA | CEFTOZIDIME+ AVIBACTAM | 2G/0,5G | PDRE PR SOL PERF | B/10F | PFIZER IRELAND PHARMA | V | CS 30/01/2024 | |
40 | ZERBAXA | CEFTOLOZZANE+ TAZOBACTAM | 1G/0,5G | PDRE PR SOL PERF | B/10F | MERCK SHARP & DOHME UK | E | V | CS 30/01/2024 |
41 | BOOSTERIX | VACCIN DIPHTERQUE TETANIQUE COQUELUCHRUX | SUSP INJ | B/1seringues préremplies | GLAXOSMITHKLINE BIOLOGICALS BELGIUM | E | V | CS 30/01/2024 | |
42 | INFANRIX HEXA | VACCIN D+T+C+P+HB+HIB | SUSP INJ | B/1FL | GLAXOSMITHKLINE BIOLOGICALS BELGIUM | E | V | CS 30/01/2024 | |
43 | RINVOQ | UPADACITINIB | 15 MG | COMP LP | B/28 | ABBVIE DEUTSCHLAND Gmbh and Co.KG | N | 31/01/2024 | |
44 | XELJANZ XR | TOFACITINIB | 11 mg | COMP LP | B/30 | Pfizer Inc USA | E | N | 31/01/2024 |
45 | XELJANZ | TOFACITINIB | 5 mg | COMP LP | B/60 | PF PRISM/PFIZER NETHERLANDS | E | V | 31/01/2024 |